BI 894999( BI894999 )

Catalog No. M12534 CAS No. 1660117-38-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

BI 894999
Note

Research use only, not for human use.
Brief Description

BI 894999 is a novel potent, selective BET inhibitor with IC50 of 5 and 41 nM for BRD4-BD1 and BRD4-BD2 bromodomains, respectively.
Description

BI 894999 is a novel potent, selective BET inhibitor with IC50 of 5 and 41 nM for BRD4-BD1 and BRD4-BD2 bromodomains, respectively; displays excellent selectivity over other bromodomains; decreases S-Phase and increases apoptosis, Volasertib augments and prolongs the decrease of MYC expression caused by BI 894999 treatment in AML cell lines; dramatically reduces tumor burden accompanied by eradication of AML cells in mouse bone marrow combined with Volasertib; also represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.Solid Tumors Phase 1 Clinical
In Vitro

——
In Vivo

——
Synonyms

BI894999
Pathway

Chromatin/Epigenetic
Target

Bromodomain
Recptor

Bromodomain
Research Area

Cancer
Indication

Solid Tumors

CAS Number

1660117-38-3
Formula Weight

429.524
Molecular Formula

C25H27N5O2
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 125 mg/mL (291.03 mM)
SMILES

CN1C(C(C)=CC(C2=NC3=CN=C(C4CCOCC4)C=C3N2[C@@H](C)C5=CC=CC=C5)=N1)=O
Chemical Name

(S)-2,4-dimethyl-6-(1-(1-phenylethyl)-6-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)pyridazin-3(2H)-one

1. Tontsch-Grunt U, et al. Cancer Lett. 2018 Feb 14;421:112-120. 2. Gerlach D, et al. Oncogene. 2018 Mar 1. doi: 10.1038/s41388-018-0150-2.

Calculator

molnova catalog